Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
135
Recruiting, any sponsor type, condition "Parkinson"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting135
- Completed1,030
135 trials
Showing 1 to 25, recently updated first.
Yale UniversityAcademic, hospital or other
NCT07610369 · 40 participants (planned) · Start Jul 10, 2026 · Primary completion Jul 2030
Drug: Psilocybin (drug); Psilocybin (drug) · For: Depression; Parkinson's Disease (PD)
Sites: New Haven, Connecticut
Georgetown UniversityAcademic, hospital or other
NCT07592767 · 30 participants (planned) · Start Sep 17, 2026 · Primary completion Jun 1, 2028
Drug: Trans-Resveratrol · For: Parkinson's Disease
Sites: Washington D.C., District of Columbia
- A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's DiseasePivotal-lookingRecruiting
Biohaven Therapeutics Ltd.Industry
NCT06976268 · 550 participants (planned) · Start May 28, 2025 · Primary completion Aug 2027
Drug: BHV-8000 10mg; BHV-8000 20 mg and 1 more · For: Parkinson Disease
Sites: Birmingham, Alabama; Sun City, Arizona; Irvine, California · 26 sites in all
Atrium TherapeuticsIndustry
NCT07738107 · 37 participants (planned) · Start Sep 14, 2026 · Primary completion May 2028
Drug: ATR 1072 · For: Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic and 1 more
Sites: Kansas City, Missouri; Houston, Texas
- Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's DiseasePivotal-lookingRecruiting
Hangzhou PhecdaMed Co., Ltd.Industry
NCT07741045 · 300 participants (planned) · Start Nov 5, 2026 · Primary completion Jan 15, 2028
Drug: TJ0113 200mg; TJ0113 400mg and 1 more · For: Parkinson's Disease (PD); Parkinson Disease 6, Early-Onset
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 21 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06952504 · 1,123 participants (planned) · Start May 22, 2025 · Primary completion May 24, 2032
Drug: Pembrolizumab; Carboplatin and 4 more · For: Endometrial Cancer
Sites: Mobile, Alabama; Anchorage, Alaska; Irvine, California · 272 sites in all
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Industry
NCT07176286 · 20 participants (planned) · Start Apr 30, 2026 · Primary completion Mar 30, 2027
Drug: 18F-MFBG · For: Parkinson Disease (PD); Lewy Body Dementia (LBD)
Sites: Houston, Texas
- Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson DiseasePivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT07187466 · 146 participants (planned) · Start Nov 9, 2026 · Primary completion Mar 31, 2030
Drug: mirabegron · For: Overactive Bladder; Parkinson Disease
Sites: Decatur, Georgia; Philadelphia, Pennsylvania; Salt Lake City, Utah
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07216703 · 1,023 participants (planned) · Start Jan 19, 2026 · Primary completion Oct 29, 2031
Drug: Pembrolizumab; Sacituzumab Tirumotecan and 5 more · For: Cervical Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Irvine, California · 189 sites in all
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06623422 · 680 participants (planned) · Start Oct 21, 2024 · Primary completion May 16, 2033
Drug: Pembrolizumab; Cisplatin and 5 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Tucson, Arizona; Fullerton, California · 247 sites in all
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06966700 · 2,400 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 23, 2033
Drug: Sacituzumab tirumotecan; Pembrolizumab and 8 more · For: Breast Neoplasms; Triple Negative Breast Neoplasms; HR Low-Positive/HER2-Negative Breast Neoplasms
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 338 sites in all
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06841354 · 1,000 participants (planned) · Start Mar 16, 2025 · Primary completion May 18, 2030
Drug: Sacituzumab tirumotecan; Pembrolizumab and 5 more · For: Triple Negative Breast Neoplasms
Sites: Mobile, Alabama; Chandler, Arizona; Duarte, California · 285 sites in all
- Study to Test Effects and Safety of RO7568282 in Early Parkinson's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07781644 · 474 participants (planned) · Start Nov 11, 2026 · Primary completion Dec 15, 2028
Drug: RO7568282; Placebo · For: Parkinson's Disease
Sites: Boca Raton, Florida; Shanghai, China; Cork, Ireland · 6 sites in all
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06989112 · 600 participants (planned) · Start Mar 27, 2025 · Primary completion Jan 19, 2029
Drug: Trastuzumab deruxtecan; Rilvegostomig and 4 more · For: Endometrial Cancer
Sites: Tucson, Arizona; Little Rock, Arkansas; Duarte, California · 256 sites in all
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06469944 · 160 participants (planned) · Start Sep 20, 2024 · Primary completion Sep 12, 2029
Drug: Pembrolizumab; Sacituzumab Tirumotecan (sac-TMT) and 6 more · For: Gastroesophageal Junction; Gastroesophageal Adenocarcinoma; Esophageal Neoplasms and 1 more
Sites: Tucson, Arizona; Los Angeles, California; Louisville, Kentucky · 50 sites in all
Prabesh KanelAcademic, hospital or other
NCT07154511 · 45 participants (planned) · Start Nov 7, 2025 · Primary completion May 2027
Drug: Tributyrin; Placebo · For: Parkinson Disease; Parkinson Disease Dementia
Sites: Ann Arbor, Michigan
- A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor FluctuationsPivotal-lookingRecruiting
H. Lundbeck A/SIndustry
NCT07514858 · 150 participants (planned) · Start Jul 28, 2026 · Primary completion Oct 3, 2028
Drug: Lu AF28996; Placebo · For: Parkinson's Disease
Sites: Boca Raton, Florida; Farmington, Michigan; Round Rock, Texas · 6 sites in all
Serina TherapeuticsIndustry
NCT07422675 · 40 participants (planned) · Start Feb 1, 2026 · Primary completion Jan 31, 2027
Drug: SER-252 (PEOZ-apomorphine) · For: PARKINSON DISEASE (Disorder); Advanced Parkinson's Disease
Sites: Englewood, Colorado; Hallandale, Florida; Maitland, Florida · 8 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06345729 · 348 participants (planned) · Start May 24, 2024 · Primary completion Jan 24, 2028
Drug: Calderasib; Pembrolizumab · For: Non-small Cell Lung Cancer
Sites: Bakersfield, California; Beverly Hills, California; Stamford, Connecticut · 248 sites in all
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07252739 · 140 participants (planned) · Start Dec 19, 2025 · Primary completion Nov 15, 2029
Drug: MK-1084; Pembrolizumab and 3 more · For: Malignant Neoplasm
Sites: Clermont, Florida; Fargo, North Dakota; Sioux Falls, South Dakota · 40 sites in all
Vima TherapeuticsIndustry
NCT07804615 · 80 participants (planned) · Start Sep 15, 2026 · Primary completion Jun 2027
Drug: VIM0423; VIM0423 Placebo · For: PARKINSON DISEASE (Disorder)
Sites: Scottsdale, Arizona; Murrieta, California; Stamford, Connecticut · 30 sites in all
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPivotal-lookingRecruiting
Reunion Neuroscience IncIndustry
NCT07002034 · 100 participants (planned) · Start Jul 30, 2025 · Primary completion Apr 2027
Drug: RE104 for Injection · For: Adjustment Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; San Diego, California · 33 sites in all
- An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)Pivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT06996652 · 108 participants (planned) · Start Aug 17, 2026 · Primary completion Aug 1, 2029
Drug: Adalimumab; Placebo · For: REM Sleep Behavior Disorder
Sites: Los Angeles, California; Aurora, Colorado; North Haven, Connecticut · 18 sites in all
Prabesh KanelAcademic, hospital or other
NCT07863180 · 15 participants (planned) · Start Oct 1, 2026 · Primary completion May 2027
Drug: Tributyrin; Placebo · For: Parkinson Disease; Multiple System Atrophy; Progressive Supranuclear Palsy(PSP)
Sites: Ann Arbor, Michigan
- A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07174310 · 900 participants (planned) · Start Nov 24, 2025 · Primary completion Jun 30, 2029
Drug: Prasinezumab; Placebo · For: Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Fullerton, California · 192 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.